Biometrics CRO Growth Oxurion owns a 72% stake in Axiodis CRO, a biometrics-focused subcontractor, signaling demand for biometrics data capture, analytics and regulatory-ready reporting in European ophthalmology trials; opportunity to upsell additional CRO services to strengthen Axiodis capabilities.

Integrated Subcontractor Platform Oxurion aims to build an integrated group of subcontractors serving healthcare stakeholders, creating opportunities for scalable due diligence, post-merger integration services, and multi-site trial management platforms across Europe.

Growth Financing Readiness Recent financing activity with Atlas and dedicated facilities for digital and crypto investments indicates strong liquidity for growth; potential to offer structured finance, treasury optimization, and investment governance support to back acquisitions and portfolio expansion.

Ophthalmic Trial Focus With a focus on next-generation ophthalmic therapies and trials such as KALAHARI, there is a market opportunity to provide specialized ophthalmic imaging, data analytics, patient recruitment and regulatory support for ocular studies.

European Expansion Headquartered in Belgium with a clear European acquisition strategy, Oxurion could partner with regional CROs and service providers to expand footprints, navigate local regulatory environments, and build a European network of trusted subcontractors.